Ticagrelor Improves Endothelial Function by Decreasing Circulating Epidermal Growth Factor (EGF)

Ticagrelor is one of the most powerful P2Y(12) inhibitor. We have recently reported that, in patients with concomitant Stable Coronary Artery Disease (SCAD) and Chronic Obstructive Pulmonary Disease (COPD) undergoing percutaneous coronary intervention (PCI), treatment with ticagrelor, as compared to...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Front Physiol
Hauptverfasser: Vieceli Dalla Sega, Francesco, Fortini, Francesca, Aquila, Giorgio, Pavasini, Rita, Biscaglia, Simone, Bernucci, Davide, Del Franco, Annamaria, Tonet, Elisabetta, Rizzo, Paola, Ferrari, Roberto, Campo, Gianluca
Format: Artigo
Sprache:Inglês
Veröffentlicht: Frontiers Media S.A. 2018
Schlagworte:
Physiology
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5900783/
https://ncbi.nlm.nih.gov/pubmed/29686623
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphys.2018.00337
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge